Analyst Ratings For Hikma Pharmaceuticals Plc (LON:HIK)
Today, Peel Hunt reiterated its Buy rating on Hikma Pharmaceuticals Plc (LON:HIK) with a price target of GBX 2,340.
There are 2 hold ratings, 9 buy ratings on the stock.
The current consensus rating on Hikma Pharmaceuticals Plc (LON:HIK) is Buy (Score: 2.82) with a consensus target price of GBX 2,300.30 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-Peel Hunt Reiterated Rating of Buy.
- 1/17/2017-J P Morgan Chase & Co Reiterated Rating of Overweight.
- 11/30/2016-AlphaValue Reiterated Rating of Buy.
- 11/16/2016-Citigroup Inc. Reiterated Rating of Neutral.
- 11/15/2016-Morgan Stanley Upgrade from a “Equal Weight ” rating to a ” Overweight” rating.
About Hikma Pharmaceuticals Plc (LON:HIK)
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company’s segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business’ products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.
Recent Trading Activity for Hikma Pharmaceuticals Plc (LON:HIK)
Shares of Hikma Pharmaceuticals Plc closed the previous trading session at 2,082.00 up +14.00 0.68% with 389,232 shares trading hands.
